Molecular Partners AG Reports Positive Results from Its First Clinical Studies
4/28/2011 10:29:06 AM
ZURICH-SCHLIEREN, Switzerland--(BUSINESS WIRE)--Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A. The DARPin molecule was shown to be safe and well tolerated in two separate Phase I/IIa trials in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
comments powered by